StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
AMBEA.ST$139.00-4.34%
Fair $139.00+0.0%

AMBEA.ST

Ambea AB (publ)

Healthcare / Medical Care FacilitiesStockholm

$139.00

-6.30 (-4.34%)

Fairly Valued+0.0%Fair Value $139.00Fund rank 33/100 · Data gapFallback financials|
SA 47/C
F-Score: 5/9
High Debt

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 23% · confianza 25%

FCF escenarios

weak_data · normalized FCF $1.9B · quality 62.0/100

Data gap 33/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 90/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

47/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Debt-to-Equity ratio is 2.43, above the 2.0 threshold
Thesis & Journal · AMBEA.STLocal privado en este navegador · Ambea AB (publ)
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$11.2B

P/E

16.3x

↓

EV/EBITDA

8.5x

↓

ROE

12.8%

↑

Gross Margin

96.5%

↑

Debt/Equity

2.43

↑
52-Week Range$139
$106$154

TradingView lightweight chart

AMBEA.ST price, volumen y niveles de valoración

Último $139.00Periodo +86.6%
Fair value: $139.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+8.3%

FCF CAGR

+15.0%

FCF margin

12.7%

FCF / Net income

3.05x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $16.04B · net income $665.0M · FCF $2.03B

2022-FY → 2025-FY

Gross margin

96.5%+0.0% pts

Operating margin

8.5%+1.8% pts

Net margin

4.1%+1.2% pts

FCF margin

12.7%+2.1% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$16.04B$16.04B$14.20B$13.31B$12.63B
Net Income$665.0M$665.0M$620.0M$455.0M$366.0M
EBITDA$2.85B$2.85B$2.62B$2.25B$2.00B
EPS7.927.927.205.073.89
Gross Margin96.5%96.5%96.5%96.5%96.5%
Operating Margin8.5%8.5%8.8%7.3%6.7%
Net Margin4.1%4.1%4.4%3.4%2.9%
Balance Sheet
Debt/Equity2.432.432.162.182.34
Current Ratio0.450.45———
Cash Flow
Free Cash Flow$2.03B$2.03B$1.95B$1.62B$1.33B
Returns
ROE12.8%12.8%12.4%9.2%7.8%
Valuation
P/E16.2816.2813.7310.4211.19
EV/EBITDA8.508.507.356.887.39
P/B2.242.241.710.960.88
Growth & Yield
Revenue Growth13.0%13.0%6.6%5.4%—
EPS Growth10.0%10.0%42.0%30.3%—
Dividend Yield1.8%1.8%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

15.9%

exigente

EPS terminal req.

$12.33

Spread vs growth

-5.9%

5Y implied EPS CAGR

13.5%

razonable

EPS terminal req.

$14.92

Spread vs growth

-3.5%

10Y implied EPS CAGR

11.7%

razonable

EPS terminal req.

$24.04

Spread vs growth

-1.7%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +30.2%

Total return

+30.2%

Start / end P/E

15.0x → 17.6x

EPS bridge

7.20 → 7.92

Residual

+1.7%

EPS growth+10.0%
Multiple rerating+16.7%
Dividend+1.8%
Residual / FX / buybacks / cross-term+1.7%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.